Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
tenecteplase
Table of contents
Overview
The marketing authorisation for Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
|
| Agency product number |
EMEA/H/C/000307
|
| Active substance |
tenecteplase
|
| International non-proprietary name (INN) or common name |
tenecteplase
|
| Therapeutic area (MeSH) |
Myocardial Infarction
|
| Anatomical therapeutic chemical (ATC) code |
B01AD
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Boehringer Ingelheim International GmbH
|
| Revision |
2
|
| Date of issue of marketing authorisation valid throughout the European Union |
23/02/2001
|
| Contact address |
Binger Strasse 173
D-55216 Ingelheim am Rhein Germany |
Product information
09/08/2005 Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG - EMEA/H/C/000307 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antithrombotic agents
Therapeutic indication
Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.